A Study of SA030 Injection in Overweight or Obese Participants

This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight or obese. Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.

NCT Number	NCT07479862
Lead Sponsor	Suzhou Siran Biotechnology Co.,Ltd.
Conditions	Obese, Overweight
Enrollment	40 participants
Start Date	2026-04-16
Primary Completion	2026-08-18 (estimated)
Study Completion	2027-03-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-18